Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130014/S022

Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant

Stryker Leibinger GmbH & Co. KG · Decision date Jul 15, 2026

FDA DECISIONP130014/S022

What did the FDA approve?

FDA records P130014/S022 as a supplement to PMA P130014, with the supplement type “Panel Track”. The recorded decision is approval, dated Jul 15, 2026.

FDA approval order statement

The Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant are indicated for use in patients who are 13 years of age and older, as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure during cranial and spinal procedures.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Neurology
Decision date
Jul 15, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P130014/S022
Regulatory pathway
PMA supplement
Product code
NQR
Decision code
APPR
Decision date
Jul 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Product code
NQR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130014/S021 · Related supplement

    Adherus AutoSpray Dural Sealant

  2. P130014/S022 received

    Application receipt date recorded by FDA.

  3. P130014/S022 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P130014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130014

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker Leibinger GmbH & Co. KGPMA supplementNov 6, 2025FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA supplementAug 31, 2026FDA
Pramand, LLCPMA supplementAug 5, 2026FDA
Pramand, LLCPMA supplementApr 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stryker Leibinger GmbH & Co. KG

Headquarters
Not reported
Brand website
stryker.com
FDA applicant address
Boetzinger Strasse 41, Freiburg, D-7911

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records